Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Research and ... of the "2015 New Frontiers in ... Technologies, Competitive Landscape" report to their ... Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging ... strategic analysis of major business opportunities emerging ...
(Date:7/2/2015)... julio de 2015 BGI anunció hoy que ... alto rendimiento en Hong Kong ... (CAP). La instalación de BGI en Hong Kong ... próxima generación que recibe la certificación CAP en ... en prácticas de laboratorio clínico. Junto con el exitoso ...
(Date:7/2/2015)... SEOUL , South Korea, July 2, 2015 ... of a new E-CUBE Series ultrasound system. Developed to ... of clinical areas, the E-CUBE 15 EX produces superb ... outstanding clinical performance in women,s health, general imaging, and ... The latest in the renowned E-CUBE Series, ...
Breaking Medicine Technology:New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI recibe la acreditación del College of American Pathologists (CAP) 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3
... University of Bari, Italy, concluded that treating patients after ... (SVR) and protects them from liver-related deaths. The purpose ... outcomes of patients posttransplant who underwent antiviral therapy for ... graft. The use in clinical practice ...
... SPRING, Md., Oct. 29 The U.S. Food ... an injectable antibiotic to treat adults with community ... and skin structure infections (ABSSSI), including methicillin-resistant ...   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ...
Cached Medicine Technology:Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes 2FDA Approves Teflaro for Bacterial Infections 2FDA Approves Teflaro for Bacterial Infections 3
(Date:7/2/2015)... Spring, Md. (PRWEB) , ... July 02, 2015 , ... ... mark in his solo cross-country walk to raise awareness and money for the ... and expects to arrive at PHA’s headquarters near Washington, D.C. by mid-September. He left ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com ... a passion for social fitness. Built to function as a lifestyle community, Active Bunch ... them the opportunity to network, meet, and participate in discussions or group events. ...
(Date:7/2/2015)... (PRWEB) , ... July 02, ... ... wound therapy (NPWT) - pipeline review 2015” provides comprehensive information on the ... development. Complete report on negative pressure wound therapy (NPWT) with 22 market ...
(Date:7/2/2015)... , ... July 02, 2015 ... ... janitorial supply company , announced today that it has reached an ... acquisition will make CleanItSupply.com the largest distributor of Rubbermaid Commercial Products on ...
(Date:7/2/2015)... ... 2015 , ... Real Time Pain Relief (RTPR), makers of the popular rub-on pain ... PBR to sponsor The Fifth Annual Big Sky Professional Bull Riders Event being held ... of their popular pain relief lotion and products at the family friendly event that features ...
Breaking Medicine News(10 mins):Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Real Time Pain Relief Sponsors The Fifth Annual Big Sky Professional Bull Riders Event at Big Sky Town Center in July 2Health News:Real Time Pain Relief Sponsors The Fifth Annual Big Sky Professional Bull Riders Event at Big Sky Town Center in July 3
... already used for high blood pressure and prostate problems ... in veterans with posttraumatic stress disorder (PTSD). ... been demonstrated effective for PTSD nightmares and sleep disruption," ... mental health service at the Veterans Affairs Puget Sound ...
... simpler than what scientists// had been assuming. A new study ... livers. It could significantly affect the way physicians make livers ... or cancer. ,"The human liver is ... regenerate from as little as 25 percent of its tissue," ...
... Britain’s junior doctors,// reports show. ,It ... street in protest of the lack of suitable jobs. This was ... pounds to train for government programs that would make them eligible ... to the Department of Health ‘s scheme, the Medical Training Application ...
... National Cancer Institute (NCI) has commended Novartis' anti-cancer tablet, ... GISTs, metastatic gastro-intestinal tumors. ,These tumours ... found in the digestive system - the gastrointestinal tract. ... control the movements of the gut. ...
... A report has come out with the suggestion that Britain’s ... curb the binge-drinking spree that is threatening to knock out ... journal published by the Institute for Public Policy Research (IPPR), ... over the regulation of alcohol. ,Gerard purports "tough ...
... on. Is Hormone Replacement Therapy (HRT), good or bad? ... which targets menopausal women by giving them measured doses of ... Its risks such as breast cancer, and heart disease often ... This was mainly due to a 2002 study conducted for ...
Cached Medicine News:Health News:BP and Prostate Problems Drug Effective in Treating PTSD Nightmares 2Health News:BP and Prostate Problems Drug Effective in Treating PTSD Nightmares 3Health News:Liver Regeneration may Be Simpler Than Previously Thought 2Health News:Liver Regeneration may Be Simpler Than Previously Thought 3Health News:UK’s Junior Doctors Losing Hop 2Health News:Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors 2Health News:Drinking Age Must Be Raised to Curb Binge Drinking-Voices Warn 2Health News:Hormone Replacement Therapy – To Choose Or No 2